Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$56.40 -1.5%	$60.81	$32.50 ▼ $86.53	$1.80B	-1.52	50,357 shs	20,439 shs
DNLI Denali Therapeutics	$12.74 +1.5%	$15.78	$10.57 ▼ $33.33	$1.85B	1.58	1.08 million shs	979,179 shs
KROS Keros Therapeutics	$14.07 +4.0%	$11.17	$9.12 ▼ $72.37	$570.71M	1.39	783,889 shs	1.35 million shs
MIRM Mirum Pharmaceuticals	$39.10 +0.9%	$45.23	$23.14 ▼ $54.23	$1.92B	1	523,007 shs	429,075 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-1.54%	-3.62%	-17.52%	+0.34%	+74.45%
DNLI Denali Therapeutics	+1.51%	+1.92%	-12.20%	-41.91%	-24.26%
KROS Keros Therapeutics	+3.99%	+14.95%	+23.96%	+29.56%	-76.26%
MIRM Mirum Pharmaceuticals	+0.90%	-0.05%	-11.76%	-16.72%	+63.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.6254 of 5 stars	3.5	5.0	0.0	1.7	0.8	0.6
DNLI Denali Therapeutics	4.0945 of 5 stars	4.5	1.0	4.7	2.9	1.7	0.0
KROS Keros Therapeutics	3.47 of 5 stars	4.3	2.0	0.0	3.1	5.0	0.0
MIRM Mirum Pharmaceuticals	3.9581 of 5 stars	3.5	0.0	4.2	3.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	71.39% Upside
DNLI Denali Therapeutics	3.00	Buy	$37.57	194.91% Upside
KROS Keros Therapeutics	2.57	Moderate Buy	$40.33	186.66% Upside
MIRM Mirum Pharmaceuticals	3.09	Buy	$58.20	48.85% Upside

Current Analyst Ratings Breakdown

Latest KROS, MIRM, BLTE, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/9/2025	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$43.00 ➝ $25.00
4/1/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00 ➝ $15.00
4/1/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/26/2025	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/18/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/18/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/10/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $28.00
3/7/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00 ➝ $33.00
3/5/2025	DNLI Denali Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $35.00
3/3/2025	DNLI Denali Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $42.00

(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
DNLI Denali Therapeutics	$330.53M	5.60	N/A	N/A	$7.42 per share	1.72
KROS Keros Therapeutics	$3.55M	160.76	N/A	N/A	$11.09 per share	1.27
MIRM Mirum Pharmaceuticals	$336.89M	5.69	N/A	N/A	$5.33 per share	7.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.18	N/A	N/A	N/A	N/A	-31.94%	-30.73%	5/12/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.57	N/A	N/A	N/A	N/A	-32.94%	-30.04%	5/6/2025 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$5.01	N/A	N/A	N/A	-27,890.94%	-41.74%	-38.42%	5/6/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.85	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	5/6/2025 (Estimated)

Latest KROS, MIRM, BLTE, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KROS Keros Therapeutics	$0.1614	N/A	N/A	N/A	$62.01 million	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	BLTE Belite Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	$3.24 million	N/A
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
2/27/2025	Q4 2024	DNLI Denali Therapeutics	-$0.75	-$0.67	+$0.08	-$0.67	$12.75 million	N/A
2/26/2025	Q4 2024	KROS Keros Therapeutics	-$1.36	-$1.14	+$0.22	-$1.14	$37.32 million	$3.04 million
2/26/2025	Q4 2024	MIRM Mirum Pharmaceuticals	-$0.27	-$0.49	-$0.22	-$0.49	$96.64 million	$99.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
DNLI Denali Therapeutics	N/A	9.98	9.98
KROS Keros Therapeutics	N/A	19.03	19.03
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
DNLI Denali Therapeutics	92.92%
KROS Keros Therapeutics	71.56%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
DNLI Denali Therapeutics	7.90%
KROS Keros Therapeutics	22.90%
MIRM Mirum Pharmaceuticals	22.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
DNLI Denali Therapeutics	430	145.22 million	132.55 million	Optionable
KROS Keros Therapeutics	100	40.56 million	31.23 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.01 million	37.03 million	Optionable

KROS, MIRM, BLTE, and DNLI Headlines

Recent News About These Companies

27,322 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Purchased by Capital Fund Management S.A.

April 18 at 4:23 AM | marketbeat.com

Geode Capital Management LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 17 at 3:23 AM | marketbeat.com

Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation

April 15 at 3:40 AM | markets.businessinsider.com

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

April 14, 2025 | msn.com

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

April 14, 2025 | finance.yahoo.com

ExodusPoint Capital Management LP Purchases Shares of 22,153 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 13, 2025 | marketbeat.com

Vanguard Group Inc. Has $100.26 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 12, 2025 | marketbeat.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2025 | businesswire.com

KLP Kapitalforvaltning AS Makes New $277,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 8, 2025 | marketbeat.com

Rhenman & Partners Asset Management AB Lowers Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 7, 2025 | marketbeat.com

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

April 5, 2025 | markets.businessinsider.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Clearbridge Investments LLC

April 3, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Pictet Asset Management Holding SA

April 1, 2025 | marketbeat.com

NEOS Investment Management LLC Sells 26,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

April 1, 2025 | marketbeat.com

Loomis Sayles & Co. L P Acquires 78,708 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

March 30, 2025 | marketbeat.com

10,000 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Purchased by Congress Wealth Management LLC DE

March 30, 2025 | marketbeat.com

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

March 28, 2025 | msn.com

Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan

March 28, 2025 | markets.businessinsider.com

LIVMARLI Now Approved in Japan for ALGS and PFIC

March 27, 2025 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from Analysts

March 25, 2025 | marketbeat.com

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

March 24, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, MIRM, BLTE, and DNLI Company Descriptions

Belite Bio NASDAQ:BLTE

$56.40 -0.88 (-1.54%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$56.28 -0.12 (-0.21%)

As of 04/17/2025 06:23 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Denali Therapeutics NASDAQ:DNLI

$12.74 +0.19 (+1.51%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$12.75 +0.01 (+0.08%)

As of 04/17/2025 04:07 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Keros Therapeutics NASDAQ:KROS

$14.07 +0.54 (+3.99%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$14.07 0.00 (0.00%)

As of 04/17/2025 05:47 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$39.10 +0.35 (+0.90%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$39.12 +0.02 (+0.04%)

As of 04/17/2025 04:20 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time